JP2020524143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524143A5 JP2020524143A5 JP2019569758A JP2019569758A JP2020524143A5 JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5 JP 2019569758 A JP2019569758 A JP 2019569758A JP 2019569758 A JP2019569758 A JP 2019569758A JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- bioactive agent
- lipid
- oil
- sorbitan ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 46
- 239000012867 bioactive agent Substances 0.000 claims 16
- 150000002632 lipids Chemical class 0.000 claims 15
- 239000004094 surface-active agent Substances 0.000 claims 14
- 239000002245 particle Substances 0.000 claims 13
- -1 sorbitan ester Chemical class 0.000 claims 13
- 239000007791 liquid phase Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 125000002091 cationic group Chemical group 0.000 claims 6
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 239000007790 solid phase Substances 0.000 claims 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000003921 oil Substances 0.000 claims 4
- 235000019198 oils Nutrition 0.000 claims 4
- 229940031439 squalene Drugs 0.000 claims 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 4
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical group CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 239000001294 propane Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims 2
- 239000001587 sorbitan monostearate Substances 0.000 claims 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 229940113164 trimyristin Drugs 0.000 claims 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229940044606 RIG-I agonist Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims 1
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000010775 animal oil Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000021310 complex sugar Nutrition 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 150000002313 glycerolipids Chemical class 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 150000002759 monoacylglycerols Chemical class 0.000 claims 1
- DDBRXOJCLVGHLX-UHFFFAOYSA-N n,n-dimethylmethanamine;propane Chemical compound CCC.CN(C)C DDBRXOJCLVGHLX-UHFFFAOYSA-N 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 claims 1
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 1
- 239000001593 sorbitan monooleate Substances 0.000 claims 1
- 229940035049 sorbitan monooleate Drugs 0.000 claims 1
- 229940083466 soybean lecithin Drugs 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000126A JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520204P | 2017-06-15 | 2017-06-15 | |
| US62/520,204 | 2017-06-15 | ||
| US201762540973P | 2017-08-03 | 2017-08-03 | |
| US62/540,973 | 2017-08-03 | ||
| US201762556291P | 2017-09-08 | 2017-09-08 | |
| US62/556,291 | 2017-09-08 | ||
| US201762563544P | 2017-09-26 | 2017-09-26 | |
| US62/563,544 | 2017-09-26 | ||
| US201762582859P | 2017-11-07 | 2017-11-07 | |
| US62/582,859 | 2017-11-07 | ||
| US201862622748P | 2018-01-26 | 2018-01-26 | |
| US201862622755P | 2018-01-26 | 2018-01-26 | |
| US62/622,748 | 2018-01-26 | ||
| US62/622,755 | 2018-01-26 | ||
| US201862669262P | 2018-05-09 | 2018-05-09 | |
| US62/669,262 | 2018-05-09 | ||
| US201862677336P | 2018-05-29 | 2018-05-29 | |
| US62/677,336 | 2018-05-29 | ||
| US201862680454P | 2018-06-04 | 2018-06-04 | |
| US62/680,454 | 2018-06-04 | ||
| PCT/US2018/037783 WO2018232257A1 (en) | 2017-06-15 | 2018-06-15 | Nanostructured lipid carriers and stable emulsions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000126A Division JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524143A JP2020524143A (ja) | 2020-08-13 |
| JP2020524143A5 true JP2020524143A5 (https=) | 2021-07-29 |
Family
ID=62948328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569758A Pending JP2020524143A (ja) | 2017-06-15 | 2018-06-15 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
| JP2024000126A Pending JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000126A Pending JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11141377B2 (https=) |
| EP (1) | EP3638207B1 (https=) |
| JP (2) | JP2020524143A (https=) |
| KR (2) | KR102673794B1 (https=) |
| CN (1) | CN111315362A (https=) |
| AU (1) | AU2018285694B2 (https=) |
| BR (1) | BR112019026615B1 (https=) |
| CA (1) | CA3067224A1 (https=) |
| ES (1) | ES3003260T3 (https=) |
| IL (1) | IL271384B2 (https=) |
| MX (4) | MX2019015076A (https=) |
| WO (1) | WO2018232257A1 (https=) |
| ZA (1) | ZA201908207B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019015076A (es) | 2017-06-15 | 2020-08-03 | Infectious Disease Res Inst | Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos. |
| US12180370B2 (en) | 2019-01-15 | 2024-12-31 | Nant Holdings Ip, Llc | Aragonite uses |
| US12514796B2 (en) | 2019-01-15 | 2026-01-06 | Nant Holdings Ip, Llc | Aragonite compositions, methods, and uses thereof |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| WO2021097347A1 (en) | 2019-11-15 | 2021-05-20 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
| CN115955959A (zh) * | 2020-02-26 | 2023-04-11 | 康普萨姆公司 | 纳米结构脂质载体递送系统、组合物和方法 |
| KR20220156933A (ko) | 2020-03-23 | 2022-11-28 | 에이치디티 바이오 코포레이션 | Rna의 전달을 위한 조성물 및 방법 |
| CN111494619B (zh) * | 2020-04-26 | 2022-03-18 | 南京农业大学 | 一种基于角鲨烯的阳离子纳米结构脂质载体免疫佐剂的制备方法 |
| WO2022051022A1 (en) * | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
| AU2021335334A1 (en) | 2020-09-04 | 2023-04-20 | Access To Advanced Health Institute | Genetically-adjuvanted rna vaccines |
| EP4048308A1 (en) | 2020-12-23 | 2022-08-31 | Infectious Disease Research Institute | Solanesol vaccine adjuvants and methods of preparing same |
| WO2022251406A1 (en) * | 2021-05-28 | 2022-12-01 | The Regents Of The University Of Michigan | Combined agonist adjuvant for coronavirus vaccine |
| IN202121031414A (https=) * | 2021-07-13 | 2023-01-13 | ||
| CN117715929A (zh) | 2021-07-29 | 2024-03-15 | 南特细胞公司 | 用于预防和治疗病毒感染和癌症的经修饰的t细胞受体 |
| KR102681030B1 (ko) * | 2021-08-02 | 2024-07-02 | 한국화학연구원 | 올리고뉴클레오타이드가 봉입된 나노입자, 이의 제조방법 및 이를 포함하는 약학적 제제 |
| US20250134991A1 (en) * | 2021-08-20 | 2025-05-01 | Thomas Jefferson University | Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same |
| EP4404977A4 (en) * | 2021-09-22 | 2025-07-30 | Hdt Bio Corp | NUCLEIC ACID SENSOR AGONIST COMPOSITIONS AND USES THEREOF |
| WO2023056202A2 (en) * | 2021-09-22 | 2023-04-06 | Hdt Bio Corp. | Compositions and methods for enhanced protein production |
| CA3232719A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Sars-cov-2 rna vaccine compositions and methods of use |
| EP4404919A4 (en) * | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| JP2024535354A (ja) * | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| WO2023048760A1 (en) * | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
| EP4460326A4 (en) * | 2022-01-07 | 2026-03-11 | Hdt Bio Corp | COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIVALENT IMMUNE RESPONSES |
| WO2023228116A1 (en) | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Intranasal administration of thermostable rna vaccines |
| KR102901149B1 (ko) * | 2022-09-05 | 2025-12-17 | 주식회사 차백신연구소 | 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법 |
| CA3266697A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN |
| CN116159145B (zh) * | 2023-01-31 | 2025-04-22 | 四川大学 | 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用 |
| CN116392586B (zh) * | 2023-04-12 | 2025-06-24 | 江苏中慧元通生物科技股份有限公司 | 一种纳米乳佐剂 |
| CN121398842A (zh) * | 2023-04-14 | 2026-01-23 | 百欧恩泰欧洲股份公司 | 用于预防或治疗结核病的rna |
| KR20260032554A (ko) * | 2023-06-29 | 2026-03-09 | 리그이뮨 아이엔씨. | 신규한 제형 |
| WO2025244961A1 (en) * | 2024-05-22 | 2025-11-27 | Merck Sharp & Dohme Llc | Processes for making stable nanoemulsion adjuvants |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| EP1088830A3 (en) | 1987-06-22 | 2004-04-07 | Medeva Holdings B.V. | Hepatitis b surface antigen particles |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
| US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
| WO1990006951A1 (en) | 1988-12-16 | 1990-06-28 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Pneumolysin mutants and pneumococcal vaccines made therefrom |
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| EP0414374B1 (en) | 1989-07-25 | 1997-10-08 | Smithkline Biologicals S.A. | Novel antigens and methods for their preparation |
| US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| ES2194839T3 (es) | 1991-07-19 | 2003-12-01 | Univ Queensland | Vacuna de papilomavirus. |
| AU2927892A (en) | 1991-11-16 | 1993-06-15 | Smithkline Beecham Biologicals (Sa) | Hybrid protein between cs from plasmodium and hbsag |
| EP1835029A1 (en) | 1992-06-25 | 2007-09-19 | Georgetown University | Papillomavirus vaccines |
| US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| ATE492289T1 (de) | 1993-03-09 | 2011-01-15 | Univ Rochester | Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| DE122007000092I1 (de) | 1994-10-07 | 2008-03-27 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
| JP3958360B2 (ja) | 1995-02-24 | 2007-08-15 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 |
| US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
| US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| AU2800797A (en) | 1996-04-05 | 1997-10-29 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| CA2281954A1 (en) | 1997-02-25 | 1998-08-27 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and methods for their use |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| EP0998557A2 (en) | 1997-07-21 | 2000-05-10 | North American Vaccine, Inc. | Modified immunogenic pneumolysin, compositions and their use as vaccines |
| GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| AU1145699A (en) | 1997-09-05 | 1999-03-22 | Smithkline Beecham Biologicals (Sa) | Oil in water emulsions containing saponins |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
| EP2218731A1 (en) | 1997-11-28 | 2010-08-18 | Merck Serono Biodevelopment | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| CZ298364B6 (cs) | 1998-02-05 | 2007-09-05 | Smithkline Beecham Biologicals S. A. | Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci |
| PL202844B1 (pl) | 1998-04-07 | 2009-07-31 | Corixa Corp | Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu |
| AU3560399A (en) | 1998-04-15 | 1999-11-01 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
| HUP0203035A3 (en) | 1998-07-14 | 2007-12-28 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
| PT1187629E (pt) | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| US6533949B1 (en) | 2000-08-28 | 2003-03-18 | Nanopass Ltd. | Microneedle structure and production method therefor |
| ES2260291T3 (es) | 2000-09-28 | 2006-11-01 | Chiron Corporation | Microparticulas para la administracion de acidos nucleicos heterologos. |
| DK2311848T3 (da) | 2002-12-23 | 2013-10-14 | Vical Inc | Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion |
| US7998119B2 (en) | 2003-11-18 | 2011-08-16 | Nano Pass Technologies Ltd. | System and method for delivering fluid into flexible biological barrier |
| JP5331340B2 (ja) | 2004-05-18 | 2013-10-30 | バイカル インコーポレイテッド | インフルエンザウィルスワクチン組成物、及びその使用方法 |
| PL2068918T5 (pl) | 2006-09-26 | 2024-12-02 | Access To Advanced Health Institute | Kompozycja szczepionki zawierająca syntetyczny adiuwant |
| BRPI0809926B8 (pt) | 2007-04-04 | 2021-05-25 | Infectious Disease Res Inst | composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora |
| US9421254B2 (en) * | 2007-09-24 | 2016-08-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunostimulatory combinations of TLR ligands and methods of use |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| NZ606591A (en) * | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| EP4115875A1 (en) * | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| JP6059220B2 (ja) | 2011-07-06 | 2017-01-18 | ノバルティス アーゲー | 核酸を含む水中油型エマルジョン |
| US10322089B2 (en) * | 2012-03-14 | 2019-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Nanoparticles, nanoparticle delivery methods, and systems of delivery |
| US8809388B2 (en) * | 2012-11-06 | 2014-08-19 | Brandeis University | Vegetable oil composition containing palm mid-fraction fat and method of reducing plasma cholesterol |
| CN109045294A (zh) * | 2013-01-10 | 2018-12-21 | 思齐乐 | 流感病毒免疫原性组合物及其应用 |
| IL263079B2 (en) * | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| MX2019015076A (es) * | 2017-06-15 | 2020-08-03 | Infectious Disease Res Inst | Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos. |
-
2018
- 2018-06-15 MX MX2019015076A patent/MX2019015076A/es unknown
- 2018-06-15 ES ES18742621T patent/ES3003260T3/es active Active
- 2018-06-15 KR KR1020207001253A patent/KR102673794B1/ko active Active
- 2018-06-15 AU AU2018285694A patent/AU2018285694B2/en active Active
- 2018-06-15 EP EP18742621.8A patent/EP3638207B1/en active Active
- 2018-06-15 WO PCT/US2018/037783 patent/WO2018232257A1/en not_active Ceased
- 2018-06-15 KR KR1020247018651A patent/KR20240096685A/ko not_active Ceased
- 2018-06-15 BR BR112019026615-1A patent/BR112019026615B1/pt active IP Right Grant
- 2018-06-15 IL IL271384A patent/IL271384B2/en unknown
- 2018-06-15 JP JP2019569758A patent/JP2020524143A/ja active Pending
- 2018-06-15 US US16/622,908 patent/US11141377B2/en active Active
- 2018-06-15 CA CA3067224A patent/CA3067224A1/en active Pending
- 2018-06-15 CN CN201880050697.XA patent/CN111315362A/zh active Pending
-
2019
- 2019-12-10 ZA ZA2019/08207A patent/ZA201908207B/en unknown
- 2019-12-13 MX MX2022013320A patent/MX2022013320A/es unknown
- 2019-12-13 MX MX2023006661A patent/MX2023006661A/es unknown
- 2019-12-13 MX MX2022013322A patent/MX2022013322A/es unknown
-
2021
- 2021-09-09 US US17/470,874 patent/US12201722B2/en active Active
-
2024
- 2024-01-04 JP JP2024000126A patent/JP2024029173A/ja active Pending
- 2024-12-11 US US18/977,878 patent/US20250241854A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524143A5 (https=) | ||
| JP7333563B2 (ja) | 脂質ナノ粒子 | |
| JP7202009B2 (ja) | ｓｉＲＮＡ細胞内送達のための脂質膜構造体 | |
| CN102245590B (zh) | 改善的氨基脂质和递送核酸的方法 | |
| Kim et al. | Nanotechnology and vaccine development | |
| Davidsen et al. | Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses | |
| JP2013531680A5 (https=) | ||
| DK2729127T3 (en) | METHODS FOR LIPOSOMES PREPARATION | |
| RU2014104092A (ru) | Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты | |
| US20170049702A1 (en) | Method to Enhance an Immune Response of Nucleic Acid Vaccination | |
| US20110177156A1 (en) | Sterol-Modified Amphiphilic Lipids | |
| Paecharoenchai et al. | Structure relationship of cationic lipids on gene transfection mediated by cationic liposomes | |
| JP7821776B2 (ja) | 効率的な核酸送達のための担体 | |
| EP3147277B1 (en) | Lipid membrane structure for sirna intracellular delivery | |
| CN1980638B (zh) | 用糖脂稳定基于脂质的佐剂制剂的组合物和方法 | |
| Wang et al. | Advances in the study of LNPs for mRNA delivery and clinical applications | |
| Perrie et al. | Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route | |
| Even-Or et al. | A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity | |
| Ahmad et al. | Liposomes and niosomes for targeted drug and gene delivery systems | |
| Porte et al. | A molecular view of lipid nanoparticles: insights into their morphology and structural plasticity | |
| JP2024535351A5 (https=) | ||
| EP4442256A1 (en) | Lipid nanoparticle compositions | |
| Wölk et al. | Investigation of binary lipid mixtures of a three-chain cationic lipid with phospholipids suitable for gene delivery | |
| JP5390059B2 (ja) | 無菌ポリヌクレオチド系薬剤の製造方法 | |
| JPWO2018181542A1 (ja) | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット |